

Oral Poster Presentation [DAY 2: Friday, June 12, 2026 | 16:20-17:20]

Oral Poster Presentation 1 [HBV 1]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
16:20-16:30	1	OP-01	589	Risk Factors for Postpartum Hepatitis Flares in Women with Chronic Hepatitis B	TIEN HK	CK Clinic, Vietnam
16:30-16:40	2	OP-02	591	Predictive value of serum HBcrAg and quantitative HBsAg for functional cure in chronic hepatitis B patients under long-term nucleos(t)ide analog therapy	PHUONG HL	CK Clinic, Vietnam
16:40-16:50	3	OP-03	424	ASSESSMENT OF LIVER FUNCTION TEST IN VEGETARIAN AND NON-VEGETARIAN	Santosh Kumar Gupta	Pokhara University, Nepal
16:50-17:00	4	OP-04	867	Statin prescription and major adverse cardiovascular events by antiviral therapy in chronic hepatitis B: a nationwide real-world study	Jisoo Lee	Soonchunhyang University
17:00-17:10	5	OP-05	425	Tenofovir Alafenamide Improves ALT and HCC Risk Stratification in Chronic Hepatitis B with Normal or Mildly Elevated ALT	Jaehong Jeong	Yonsei University
17:10-17:20	6	OP-06	324	Cas9-gRNA Circular Templates Reduce Hepatitis B Virus Replication via cccDNA Degradation	Deok Hwa Seo	The Catholic University of Korea

Oral Poster Presentation 2 [MASLD & ALD, Basic]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
16:20-16:30	1	OP-07	964	A Study to Evaluate the Impact of Zinc Deficiency on Liver Fibrosis in Lean Vs. Obese Metabolic Dysfunction-Associated Steatotic Liver Disease Patients	Archana Chaudhari	GMERS Medical College and Hospital, India
16:30-16:40	2	OP-08	368	Mechanistic Study on the Protective Role of ApoJ in Alleviating Lipid Peroxidation in Alcoholic Liver Disease via Regulation of the Nrf2-SLC7A11 Axis	YuanxiJiang	Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases, China
16:40-16:50	3	OP-09	417	Differential Activation of Complement system Drives Immune Cell Differentiation to Promote Nonalcoholic Fatty Liver Disease Progression	Hao Xing	Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases, China
16:50-17:00	4	OP-10	304	Fibroblast- and macrophage-derived thrombospondin-1 orchestrates the fibroinflammatory niche in metabolic dysfunction-associated steatohepatitis-induced fibrosis	Sung Woo Cho	The Catholic University of Korea
17:00-17:10	5	OP-11	384	Zonation-Dependent Enrichment and Spatial Remodeling of Intrahepatic CD3+ T Cells in MASLD Fibrosis	Min Su Cha	The Catholic University of Korea
17:10-17:20	6	OP-12	701	Establishment of a CO ₂ -Independent Platform for iPSC-Derived Hepatocyte Differentiation to Enable 3D Bioprinting in Space	Chae Eun LEE	Hanyang University

Oral Poster Presentation 3 [MASLD & ALD, Clinical]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
16:20-16:30	1	OP-13	709	Patterns of Alcohol Consumption and Clinical Spectrum of Alcohol-Related Liver Disease in a Rural Setting in Nepal: A Hospital-Based Study	Rekha Poudel	Mediplus Hospital and Trauma Center, Nepal
16:30-16:40	2	OP-14	987	Multi-Domain Computational Phenotyping Identifies Distinct Hepatic Fragility Architectures Across Sexual and Gender Minority Adults Integrating Preventive Gaps, Metabolic Liver Injury, Alcohol Exposure, and Care Fragmentation	Rini Winarti	NextGen Biology & Health Equity Research Network, Indonesia
16:40-16:50	3	OP-15	310	Clonal Hematopoiesis of Indeterminate Potential and Metabolic Dysfunction-Associated Steatotic Liver Disease: Comprehensive Analysis of Biopsy-Proven Cohorts	Yun Kyu Lee	Seoul National University
16:50-17:00	4	OP-16	634	Trends in the Prevalence of Steatotic Liver Disease and Its Subtypes in Korea: A Nationwide Population-Based Study (2007–2023)	Jun Sik Yoon	Inje University
17:00-17:10	5	OP-17	1000	Multiparametric Ultrasound for the Evaluation of MASLD: An Individual Patient Data Meta-Analysis and External Validation of Prediction Models for MASH and At-Risk MASH	Dong Ho Lee	Seoul National University
17:10-17:20	6	OP-18	154	Referral burden and second-tier testing in two-step algorithms for detecting significant hepatic fibrosis among Asian community-based type 2 diabetes mellitus	Ye Ji Kwon	Hanyang University

Oral Poster Presentation [DAY 2: Friday, June 12, 2026 | 16:20-17:20]

Oral Poster Presentation 4 [LC & Liver Failure, Autoimmune Disease 1]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
16:20-16:30	1	OP-19	412	Impact of Glycemic Control on Liver-related Events in Patients with Hepatitis B Virus-related Cirrhosis and Type 2 Diabetes Mellitus	Dong Yun Kim	Yonsei University
16:30-16:40	2	OP-20	679	Hepatic Safety and Clinical Outcomes of Fexuprazan Compared with Proton Pump Inhibitors in Patients with Liver Cirrhosis	Jun Sik Yoon	Inje University
16:40-16:50	3	OP-21	706	The Paradigm Shift Toward DOACs in Liver Cirrhosis: A Longitudinal Analysis of Prescription Dynamics and Clinical Outcomes	Jeong-Ju Yoo	Soonchunhyang University
16:50-17:00	4	OP-22	578	Integrative Signed Network and Literature Mining Framework Identifies Novel Molecular Regulators of Liver Fibrosis	Wonhyo Seo	Ewha Womans University
17:00-17:10	5	OP-23	279	SE-1 Antibody-Mediated Surface Engineering of MSC-Derived Exosomes Enables Selective Targeting of Liver Sinusoidal Endothelial Cells	JINSUK LEE	Yonsei University Wonju
17:10-17:20	6	OP-24	390	An Investigation into the Effects of Microplastic Exposure on Hepatic Function Through Hydro-Dynamic Injection	Yujin Lee	Kyungpook National University

Oral Poster Presentation 5 [Liver Transplantation 1]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
16:20-16:30	1	OP-25	8	Pink1/Parkin Signaling Regulates Liver Regeneration by Modulating Sigma-1 Ubiquitination and Hepatocyte Succinate Production	Jian Xu	Nanjing Medical University, China
16:30-16:40	2	OP-26	874	ASPARTATE AMINOTRANSFERASE (AST) LEVEL ON DAY 4 AS A PREDICTOR OF STEROID RESPONSE IN BIOPSY PROVEN REJECTION AFTER LIVER TRANSPLANTATION.	Radhika Venugopal	Dr. Rela Institute and Medical Centre, India
16:40-16:50	3	OP-27	338	Recurrent Autoimmune Hepatitis after Liver Transplantation in a Young Woman: A Case Report with Histological Overlap of Chronic Rejection	Gulbanu Pernebayeva	National Research Oncology Center, Kazakhstan
16:50-17:00	4	OP-28	703	Extra-Anatomical Portal Inflow Reconstruction Using Splanchnic and Collateral Veins in Living Donor Liver Transplantation for Portal Vein Thrombosis	Young-In YOON	University of Ulsan
17:00-17:10	5	OP-29	925	Safety and Feasibility of Left Lobe Graft in Living Donor Liver Transplantation: A Comparative Study with Right Lobe Graft	Eunjin Lee	Samsung Medical Center
17:10-17:20	6	OP-30	667	Engineering Immune-Evasive Vascularized Liver Modules Using Crispr-Edited Hypoimmune Stem Cells	Hee Ju KIM	Hanyang University

Oral Poster Presentation 6 [HCC, Basic 1]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
16:20-16:30	1	OP-31	375	A novel copper ionophore A3 combined with PX-478 induces cuproptosis and enhances immunogenic cell death in hepatocellular carcinoma	Yuntao Bao	Guangxi Medical University, China
16:30-16:40	2	OP-32	355	Nidogen 1 mRNA Vaccine Facilitates T Cell Homing and Induces Anti-tumor immunity against Hepatocellular Carcinoma	Xia Lu	University of Macau, Macau
16:40-16:50	3	OP-33	66	High ammonia promotes EHHADH-dependent pyrimidine degradation to induce cell death in HCC	Jinhui Wei	Guangdong Provincial People's Hospital, China
16:50-17:00	4	OP-34	986	Exosomal miR-30a-5p Serves as a Predictive Biomarker and Therapeutic Target for Atezolizumab/Bevacizumab Therapy in Advanced HCC	Eunho Choi	Korea university
17:00-17:10	5	OP-35	429	Baseline Peripheral Blood Frequency of CD69+ TRM-Like T Cells Predicts Response to Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma	Min Seo Park	The Catholic University of Korea
17:10-17:20	6	OP-36	447	PLD1 Knockdown Suppresses Hepatocellular Carcinoma growth and progression Through Upregulation of IGFALS	Ha Neul Kim	Chungnam National University

Oral Poster Presentation [DAY 2: Friday, June 12, 2026 | 16:20-17:20]

Oral Poster Presentation 7 [HCC, Clinical 1]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
16:20-16:30	1	OP-37	496	GAAD Score as a Diagnostic and Prognostic Marker from Cirrhosis to Hepatocellular Carcinoma	Silvia Cagnin	University of Padova, Italy
16:30-16:40	2	OP-38	877	Stereotactic body radiation therapy as an add-on to targeted agents in patients with locally advanced hepatocellular carcinoma: a systematic review and meta-analysis	Mohamed Hamouda Elkasaby	Al-Azhar University, Egypt
16:40-16:50	3	OP-39	68	Identifying the novel target and immunotherapy strategies for the precision treatment of hepatocellular carcinoma	HONGPING XIA	Southeast University, China
16:50-17:00	4	OP-40	568	An Anchored Matching-Adjusted Indirect Comparison of First-Line Systemic Therapies in Advanced HCC	Ji Won Han	The Catholic University of Korea
17:00-17:10	5	OP-41	516	Thioredoxin as a novel sensitive marker of early diagnosis in hepatocellular carcinoma	Tae Hee Lee	Dongseo University
17:10-17:20	6	OP-42	137	Multicenter Propensity-Weighted Comparison of Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Atezolizumab–Bevacizumab	Kwon Yong Tak	The Catholic University of Korea

Oral Poster Presentation 8 [HCC, Clinical 2]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
16:20-16:30	1	OP-43	99	Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study	Jaejun Lee	The Catholic University of Korea
16:30-16:40	2	OP-44	125	Sequential Transarterial Radioembolization and Atezolizumab plus Bevacizumab Improves Survival in Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis	Yunmi Ko	Inha University
16:40-16:50	3	OP-45	678	Surgical Resection Versus Non-Surgical Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis	Seok-Hwan Kim	Chungnam National University
16:50-17:00	4	OP-46	21	Evaluating the Clinical Utility of Large Language Models for Hepatocellular Carcinoma Treatment Recommendations: A Nationwide Registry Study	Keungmo Yang	The Catholic University of Korea

Oral Poster Presentation 9 [Surgery, Technical Issues]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
16:20-16:30	1	OP-47	7	Comparison of surgical outcomes between robotic and laparoscopic liver resection	Ulil Albab Habibah	Islamic University Indonesia, Indonesia
16:30-16:40	2	OP-48	293	Nursing Knowledge and Its Role in Early Detection of Postoperative Complications in Liver Surgery	Hanna Rosanti	Atmajaya University, Indonesia
16:40-16:50	3	OP-49	219	LAPAROSCOPIC SURGERY FOR LIVER ECHINOCOCCUS	Mylytkbay Rysmakhanov	West-Kazakhstan Medical University, Kazakhstan
16:50-17:00	4	OP-50	96	Surgery for Hepatocellular Carcinoma Patients with Portal Vein Main Trunk Thrombosis (Vp4): Initial Experience of a Single Center.	Giang Nguyen	Vietnam National Hospital of Tropical Disease, Vietnam
17:00-17:10	5	OP-51	308	Multi-Omics Biomarkers Predicting Immune Dysregulation and Inflammation After Hepatocellular Carcinoma Resection	Ni Made Ratih Dewi	The Pranala Institute, Indonesia
17:10-17:20	6	OP-52	72	OVERCOMING THE LACK OF DEDICATED VASCULAR CLAMPS IN LAPAROSCOPIC ANATOMICAL LIVER RESECTION: THE "DOUBLE FOLEY LOOP" TECHNIQUE AS A COST-EFFECTIVE ALTERNATIVE	NGUYEN KIEU HUNG	National Hospital for Tropical Diseases, Vietnam

Oral Poster Presentation [DAY 2: Friday, June 12, 2026 | 16:20-17:20]

Oral Poster Presentation 10 [Others]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
16:20-16:30	1	OP-53	857	A retrospective study of endogenous endophthalmitis-related pyogenic liver abscess: An increasing complication in North Vietnam	Nguyen Duc Thang	Bach Mai Hospital, Vietnam
16:30-16:40	2	OP-54	490	Mobile Self-Management Coaching Program for Chronic Liver Disease with Metabolic Risk Factors in Middle-Aged Men : A Pilot Randomized Controlled Trial	Seo Jin Lee	Yonsei University
16:40-16:50	3	OP-55	828	Chirality-Dependent Nanoparticle Activation of Dendritic Cells Induces Inflammasome-Associated Inflammatory Responses to Drive Liver Inflammation	Damin Han	Kangwon National University
16:50-17:00	4	OP-56	853	Deacetylated α -tubulin in biliary epithelial cells drives hepatic ductular reaction	Ho Jae Ryu	Seoul National University
17:00-17:10	5	OP-57	975	Quantum-Informed Molecular Representation Learning for Preclinical Drug-Induced Liver Injury Prediction	Seoeun Park	Handong Global University
17:10-17:20	6	OP-58	865	Complacency, Knowledge, And Awareness Across The Hepatitis Care Cascade: A Population-Based Survey	Hanul Park	Korea University

Oral Poster Presentation [DAY 3: Saturday, June 13, 2026 | 08:00-09:00]

Oral Poster Presentation 11 [HBV 2]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
08:00-08:10	1	OP-59	601	HBV Infection Accelerates Hepatocyte Senescence and Induces T Cell Exhaustion via SASP Secretion Pathway	Ran Zhao	Tongji Medical College, China
08:10-08:20	2	OP-60	563	Presence of Salivary Hepatitis Delta Virus in HBV (Hepatitis B Virus) Infected Individuals: A New Approach to Public Health Monitoring in Resource-Limited Settings	SUMIT KUMAR RAWAT	Govt Bundelkhand Medical College Sagar Mp, India
08:20-08:30	3	OP-61	303	Age-Standardized Trends In Chronic Viral Hepatitis In Mongolia: Implications For HBV, HCV, And Delta Co-Infection Burden (2022–2024)	Nyam Biziya	Dornod Medical Center, Mongolia
08:30-08:40	4	OP-62	316	Clinical and Biochemical Characteristics of Acute Hepatitis B and Viral Coinfections in Hospitalized Patients in Mongolia	Oyungerel, Lkhagva-Ochir	Liver Center, Mongolia
08:40-08:50	5	OP-63	370	Hepatic Biochemical Abnormalities in Chronic Hepatitis B: Evidence from a Tertiary Care Hospital in Nepal	Arun Bahadur Chand	Kist Medical College & Teaching Hospital, Nepal
08:50-09:00	6	OP-64	427	Subtype-Specific Resistance Patterns and Clinical Outcomes in HCV Genotype 6 Under DAA Therapy	Jeegneshkumar B. Satani	Nanduba Medical Center, India

Oral Poster Presentation 12 [HBV & HCV]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
08:00-08:10	1	OP-65	311	Current Status of Acute HCV Infection in Mongolia (2024–2025)	DULGUUN, Batdelger	National Center for Communicable Diseases, Mongolia
08:10-08:20	2	OP-66	106	Study of the Association Between Liver Fibrosis and Renal Impairment in Chronic Hepatitis C	Gantogtokh Dashjams	Institute of Medical Sciences, Mongolia
08:20-08:30	3	OP-67	618	Exploring Predictors of Hepatitis C Treatment Uptake Among People Who Use Drugs (PWUDs): A Prospective, Multicenter Study	Gwang Hyeon Choi	Seoul National University
08:30-08:40	4	OP-68	473	Associated factors of HCV transmission between couples using National Health Insurance Data	Hwa Young Choi	National Cancer Center
08:40-08:50	5	OP-69	663	Re-engagement to rescue therapy with sofosbuvir/velpatasvir/voxilaprevir in hepatitis C after direct-acting antiviral failure	Jae Seung Lee	Yonsei University
08:50-09:00	6	OP-70	567	Real-world Effectiveness and Safety of Pangenotypic Direct-acting Antivirals in Patients with Chronic Hepatitis C: A Large-scale Multicenter Cohort Study	Myeong Jun Song	The Catholic University of Korea

Oral Poster Presentation [DAY 3: Saturday, June 13, 2026 | 08:00-09:00]

Oral Poster Presentation 13 [MASLD, Clinical]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
08:00-08:10	1	OP-71	408	Fat-to-Muscle Ratio and Subtype-Specific Protective Effects of Exercise in Steatotic Liver Disease: A Large-Scale Cohort Study	Hana Park	Konkuk University
08:10-08:20	2	OP-72	796	Impact of Hyperuricemia on the Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	Aryoung Kim	Inje University
08:20-08:30	3	OP-73	112	Safety and efficacy of Lactobacillus delbrueckii subsp. lactis CKDB001 in metabolic-associated steatotic liver disease: A randomized, double-blind, placebo-controlled trial	Jung Hee Kim	Hallym university
08:30-08:40	4	OP-74	911	Differential Prognostic Roles of Muscle and Adiposity in MASLD: Insights from MRI-Based Body Composition Analysis	Keungmo Yang	The Catholic University of Korea
08:40-08:50	5	OP-75	150	The MASLD Journey in the General Population: Linkage-to-care and Patient-Reported Uptake of Fibrosis Risk Assessment	Joo Hyun Oh	CHA university
08:50-09:00	6	OP-76	900	Development and Validation of an AI-based Prediction Model for Cardiovascular Disease Events in Patients with MASLD	Yewon Park	Chung-Ang University

Oral Poster Presentation 14 [LC Basic & Liver Failure, Autoimmune Disease 2]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
08:00-08:10	1	OP-77	383	Current Status and Prognosis of Autoimmune Hepatitis Based on the Japanese AIH Registry	Atsushi Tanaka	Teikyo University, Japan
08:10-08:20	2	OP-78	263	Noninvasive Risk Stratification of Advanced Fibrosis in Autoimmune Liver Disease Using Machine Learning	Ben George Ephrem	University of Technology and Applied Sciences, Oman
08:20-08:30	3	OP-79	502	Hepatocyte ApoJ accelerates injury-induced liver fibrosis by orchestrating Ranbp2-mediated SUMOylation and subsequent STAT3 activation	Shanyu Zhao	The First Affiliated Hospital of Guangxi Medical University, China
08:30-08:40	4	OP-80	9	Succinate-SUCNR1 Signaling in Endothelial Contributes to Liver Fibrosis Progression	Jian Xu	The First Affiliated Hospital with Nanjing Medical University, China
08:40-08:50	5	OP-81	54	VCAM serves as a potential biomarker in paediatric portal hypertension	Tengfei Si	The First Affiliated Hospital with Nanjing Medical University, China
08:50-09:00	6	OP-82	203	Anti-STC1 as a Therapeutic Strategy for Liver Fibrosis	Regina Lo	The University of Hong Kong, Hong Kong

Oral Poster Presentation 15 [LC & Liver Failure, Autoimmune Disease 3]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
08:00-08:10	1	OP-83	647	Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients with Primary Biliary Cholangitis Treated with Seladelpar: 30 Months of ASSURE	Jeong Heo	Pusan National University
08:10-08:20	2	OP-84	918	Human albumin infusion for large-volume paracentesis in liver cirrhosis: a systematic review and meta-analysis	Jae Seung Lee	Yonsei University
08:20-08:30	3	OP-85	87	Serum Albumin Response to Intravenous Albumin and Its Association with Short-Term Prognosis in Patients with Acute Decompensated Cirrhosis	Seul Ki Han	Yonsei University Wonju
08:30-08:40	4	OP-86	881	Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) for the Differential Diagnosis and Prognosis of Acute Kidney Injury in Liver Cirrhosis: A Systematic Review and Meta-Analysis	Seong Hee Kang	Korea University
08:40-08:50	5	OP-87	633	Ascites Microbiome Alterations Associated with Hepatocellular Carcinoma in Patients with Decompensated Cirrhosis	Jun Sik Yoon	Inje University
08:50-09:00	6	OP-88	407	Trends in Prevalence, Etiology, and Healthcare Costs of Cirrhosis in Korea (2008–2023): A National Population-Based Study	Hana Park	Konkuk University

Oral Poster Presentation [DAY 3: Saturday, June 13, 2026 | 08:00-09:00]

Oral Poster Presentation 16 [MASLD, Basic & Clinical]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
08:00-08:10	1	OP-89	477	Fumaric Acid as a Novel Metabolite Biomarker for Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis in Obese Subjects	Yoonseok Lee	Gil Medical Center
08:10-08:20	2	OP-90	684	Extending Stemness and Longevity of Human Chemically Derived Hepatic Progenitors Using a Novel Drug	Seunghee KIM	Hanyang University
08:20-08:30	3	OP-91	565	Long-Term Risk of Metabolic dysfunction-Associated Steatotic Liver Disease After Thyroidectomy and Thyroid Hormone Therapy in Thyroid Cancer Survivors: A Nationwide Study	Yeonjung Ha	CHA University
08:30-08:40	4	OP-92	41	Emerging Indices Outperform Traditional Fibrosis Scores in Young MASLD Across Divergent Screening Goals	Ahlim Lee	The Catholic University of Korea
08:40-08:50	5	OP-93	484	Prospective Evaluation of Steatosis Noninvasive Tests for Two-Year Monitoring in MASLD	Yoonseok Lee	Gil Medical Center
08:50-09:00	6	OP-94	426	CXCR4-Expressing Peripheral CD8 T Cells Are Activated and Recruited to the Liver in Alcohol-Associated Liver Disease	Gil Won Lee	The Catholic University of Korea

Oral Poster Presentation 17 [Liver Transplantation 2]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
08:00-08:10	1	OP-95	332	Early Postoperative C3a Predicts Early Allograft Dysfunction After Liver Transplantation	Nazokat Rustamova	Academy of Sciences Uzbekistan, Uzbekistan
08:10-08:20	2	OP-96	720	Body Mass Index ≥ 34 KG/M ² Does Not Compromise Safety or Hepatic Regeneration in Living Liver Donors: A Propensity-Matched Cohort Study	Selvakumar NAGANATHAN	Max Healthcare Institute, India
08:20-08:30	3	OP-97	58	Long-term Outcomes of the First Donor Hemighepatectomy Using 3D Laparoscopy in Kazakhstan: Experience from a Single Center	Gani Kuttymuratov	University Medical Center, Kazakhstan
08:30-08:40	4	OP-98	724	GRWR 0.7% Is a Safe Threshold in Standard Living Donor Liver Transplantation: Outcome Analysis of 2,506 Cases	Selvakumar NAGANATHAN	Max Healthcare Institute, India
08:40-08:50	5	OP-99	128	The Addition of an mTOR Inhibitor Is Associated With Increased Gut Microbial Diversity in Liver Transplant Recipients: A Prospective Pilot Study	Soon Kyu Lee	The Catholic University of Korea
08:50-09:00	6	OP-100	704	Left Lobe Liver Transplantation Using a Flipped Technique: Comparable Survival with Improved Portal Vein Alignment	Young Jin YOO	Yonsei University

Oral Poster Presentation 18 [HCC, Basic 2]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
08:00-08:10	1	OP-101	247	Targeting cell surface LANCL1 with Monoclonal Antibodies Suppresses Tumorigenesis in Hepatocellular Carcinoma	Yu Man Tsui	The University of Hong Kong, Hong Kong
08:10-08:20	2	OP-102	803	Spatially Resolved Transcriptomics Reveals Terminal CD8 ⁺ T Cell Exhaustion Driven by Chronic Inflammatory Signaling as a Key Determinant of Poor Response to Atezolizumab plus Bevacizumab in Advanced HCC	Sungjun Jang	Korea University
08:20-08:30	3	OP-103	531	Development of in vitro tumor microenvironment model for immunotherapy optimization and synergistic effects of uPAR Inhibitor in hepatocellular carcinoma immunotherapy	Yoongi Chae	Gachon University
08:30-08:40	4	OP-104	110	Multi cohort Integrative Profiling of Cytochrome P450 Genes Identifies CYP2R1 as a Metabolic and Immunogenomic Biomarker Linking DNA Repair and Myeloid Suppression in Hepatocellular Carcinoma	Hyun Sun Jung	Ajou University
08:40-08:50	5	OP-105	906	Shelterin Component TPP1 Drives Tumor Progression and Predicts Poor Prognosis in Hepatocellular Carcinoma	Jung Eun Jang	The Catholic University of Korea
08:50-09:00	6	OP-106	689	Clustering of Intrahepatic Cholangiocarcinoma Subtypes Using Whole-Genome Sequencing	Sung Hyun KIM	Yonsei University

Oral Poster Presentation [DAY 3: Saturday, June 13, 2026 | 08:00-09:00]

Oral Poster Presentation 19 [HCC, Clinical 3]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
08:00-08:10	1	OP-107	807	Prognostic factor and risk stratification in hepatocellular carcinoma: insights from Cox regression and Kaplan-Meier analysis in a male-dominated cohort	Nguyen Thanh Tung	Bach Mai Hospital, Vietnam
08:10-08:20	2	OP-108	142	Real-World Effectiveness of the STRIDE Regimen in Hepatocellular Carcinoma: Initial Experience from a Tertiary Center in Vietnam	Manh Duy Pham	Hanoi Medical University, Vietnam
08:20-08:30	3	OP-109	393	Real-World Clinical Outcomes of Nivolumab plus Ipilimumab for Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study	Tomoharu Yamada	The University of Tokyo, Japan
08:30-08:40	4	OP-110	574	MRI-Based Surveillance for Hepatocellular Carcinoma Using Risk-Stratified Screening Intervals in Patients with Cirrhosis: A Prospective Cohort Study	Byeong Geun Song	Sungkyunkwan University
08:40-08:50	5	OP-111	717	Comparative Effectiveness of Subsequent Systemic Therapies After Atezolizumab–Bevacizumab Failure in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis	Moon Haeng Hur	Seoul National University
08:50-09:00	6	OP-112	721	External Beam Radiotherapy versus Local Ablation Therapy for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis	Seo Hee Choi	Yonsei University

Oral Poster Presentation 20 [Biliary and Pancreatic Disease, Others]

Time	Abstract No.			Subject	Presenting Author	Institution/Affiliation
08:00-08:10	1	OP-113	74	Self-supervised Learning Model Integrates Plain and Contrast-enhanced CT for Preoperatively Identifying Gangrenous Cholecystitis: A Multicenter Study	Guandou Yuan	The First Affiliated Hospital of Guangxi Medical University, China
08:10-08:20	2	OP-114	577	Staged minimally invasive strategy for the management of complicated gallstone disease in pregnancy	Kyzhyrov Daulet	Kazakh National Medical University, Kazakhstan
08:20-08:30	3	OP-115	88	Survival analysis of peritoneal metastasis in pancreatic cancer receiving hyperthermic intraperitoneal chemotherapy	YAOLIN XU	Fudan University, China
08:30-08:40	4	OP-116	876	Antibiotic Prophylaxis in Emergency Cholecystectomy: A Systematic Review and Meta-Analysis with Trial Sequential Analysis	Mohamed Hamouda Elkasaby	Al-Azhar University, Cairo, Egypt
08:40-08:50	5	OP-117	683	Minimally Invasive versus Open Pancreatoduodenectomy for Upfront Resectable Pancreatic Cancer: Oncologic Outcomes and Adjuvant Chemotherapy Compliance in a Propensity Score-Matched Analysis	Keechan KAN	Yonsei University
08:50-09:00	6	OP-118	626	Low Prealbumin Predicts Early Recurrence After Pancreatic Cancer Surgery: A Retrospective Cohort Study	Myeong Hun Oh	Pusan National University

